Bvf Inc Mirati Therapeutics, Inc. Transaction History

Bvf Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 14, 2020	SELL	$70.76 - $128.86 $21.9 Million - $39.8 Million	-308,984 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$77.91 - $109.6 $17 Million - $23.9 Million	-218,269 Reduced 41.4%	308,984 $24.1 Million
Q2 2019 Aug 14, 2019	BUY	$59.49 - $104.71 $5.68 Million - $10 Million	95,553 Added 22.13%	527,253 $54.3 Million
Q1 2019 May 15, 2019	SELL	$43.65 - $78.95 $11.2 Million - $20.3 Million	-257,151 Reduced 37.33%	431,700 $31.6 Million
Q4 2018 Feb 14, 2019	SELL	$32.0 - $47.43 $1.1 Million - $1.63 Million	-34,471 Reduced 4.77%	688,851 $29.2 Million
Q3 2018 Nov 14, 2018	SELL	$47.1 - $62.7 $1.02 Million - $1.36 Million	-21,678 Reduced 2.91%	723,322 $34.1 Million
Q2 2018 Aug 14, 2018	BUY	$26.05 - $52.4 $19.4 Million - $39 Million	745,000 New	745,000 $36.7 Million

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Bvf Inc, based on Form 13F filings with the SEC.

Stay updated on Bvf Inc with notifications on news.